ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

PRM.GB Proteome Sciences Plc

4.00
0.00 (0.00%)
28 Mar 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type Share ISIN Share Description
Proteome Sciences Plc AQSE:PRM.GB Aquis Stock Exchange Ordinary Share GB0003104196
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.00 2.50 5.00 4.00 3.1248 4.00 10,000 16:29:58
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Proteome Sciences PLC Notice of Results (5346U)

29/03/2023 7:00am

UK Regulatory


Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart


From Mar 2022 to Mar 2024

Click Here for more Proteome Sciences Charts.

TIDMPRM

RNS Number : 5346U

Proteome Sciences PLC

29 March 2023

29 March 2023

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Notice of Results

The Directors of Proteome Sciences look forward to updating shareholders on the Company's performance, and on the outlook for 2023, at the time of announcing the 2022 full year results which are scheduled for announcement on Tuesday 4 April 2023.

For further information please contact:

 
 
   Proteome Sciences plc 
 Dr. Mariola Soehngen, Chief Executive        Tel: +44 (0)20 7043 2116 
  Officer 
  Dr. Ian Pike, Chief Scientific Officer 
 Richard Dennis, Chief Commercial Officer 
  Abdelghani Omari, Chief Financial Officer 
 
 Allenby Capital Limited (Nominated Adviser & Broker) 
 John Depasquale / Jeremy Porter              Tel: +44 (0) 20 3328 5656 
 
 

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant(R) and TMT(R)MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator(TM) provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORFLFFDVFITFIV

(END) Dow Jones Newswires

March 29, 2023 02:00 ET (06:00 GMT)

1 Year Proteome Sciences Chart

1 Year Proteome Sciences Chart

1 Month Proteome Sciences Chart

1 Month Proteome Sciences Chart

Your Recent History

Delayed Upgrade Clock